Company intelligence / Profile preview

Formycon AG

Munich, Bavaria, Germanyformycon.com ↗

Ownership: Public · FYB
Development stage: Commercial

Overview

Formycon AG is a leading independent developer of high-quality biosimilars, focusing on treatments in ophthalmology, immunology, and other chronic diseases. The company covers the full value chain from pharmaceutical development through clinical trials to regulatory submission. Its products target highly regulated markets such as the EU, US, Canada, Japan, and Australia. The company leverages deep expertise from its scientific team—many of whom have contributed to bringing some of the world’s first biosimilars to market—and aims to broaden patient access globally.

Therapeutic areas: ImmunologyOtherOphthalmology
Modalities: BiosimilarsMonoclonal antibodies (mAbs) and other protein-based therapeutics
Industry: Biotech

Drug pipeline

7 assets

baiama

Approved

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $6M
Total revenue: $0
Enterprise value: $11M

Beyond the preview

Go deeper on Formycon AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Formycon AG.

Explore the full profile